Jon Danel Solano-Iturri1,2,3, Enrique Echevarría4, Miguel Unda5, Ana Loizaga-Iriarte5, Amparo Pérez-Fernández5, Javier C Angulo6, José I López3,7, Gorka Larrinaga3,4,8. 1. Department of Pathology, Donostia University Hospital, 20014 Donostia/San Sebastian, Spain. 2. Department of Medical-Surgical Specialities, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain. 3. Biocruces-Bizkaia Health Research Institute, 48903 Barakaldo, Spain. 4. Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain. 5. Department of Urology, Basurto University Hospital, University of the Basque Country (UPV/EHU), 48013 Bilbao, Spain. 6. Clinical Department, Faculty of Medical Sciences, European University of Madrid, 28905 Getafe, Spain. 7. Department of Pathology, Cruces University Hospital, 48903 Barakaldo, Spain. 8. Department of Nursing, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
Abstract
(1) Background: Renal cancer is one of the most frequent malignancies in Western countries, with an unpredictable clinical outcome, partly due to its high heterogeneity and the scarcity of reliable biomarkers of tumour progression. (Pro)renin receptor (PRR) is a novel receptor of the renin-angiotensin system (RAS) that has been associated with the development and progression of some solid tumours by RAS-dependent and -independent mechanisms. (2) Methods: In this study, we analysed the immunohistochemical expression of PRR at the centre and border in a series of 83 clear-cell renal cell (CCRCCs), 19 papillary (PRCC) and 7 chromophobe (ChRCC) renal cell carcinomas, and the benign tumour renal oncocytoma (RO, n = 11). (3) Results: PRR is expressed in all the tumour subtypes, with higher mean staining intensity in ChRCCs and ROs. A high expression of PRR at the tumour centre and at the infiltrative front of CCRCC tissues is significantly associated with high grade, tumour diameter, local invasion and stage, and with high mortality risk by UCLA integrated staging system (UISS) scale. (4) Conclusions: These findings indicate that PRR is associated with the development and progression of renal tumours. Its potential as a novel biomarker for RCC diagnosis/prognosis and as a promising therapeutic target should be taken into account in the future.
(1) Background: Renal cancer is one of the most frequent malignancies in Western countries, with an unpredictable clinical outcome, partly due to its high heterogeneity and the scarcity of reliable biomarkers of tumour progression. (Pro)renin receptor (PRR) is a novel receptor of the renin-angiotensin system (RAS) that has been associated with the development and progression of some solid tumours by RAS-dependent and -independent mechanisms. (2) Methods: In this study, we analysed the immunohistochemical expression of PRR at the centre and border in a series of 83 clear-cell renal cell (CCRCCs), 19 papillary (PRCC) and 7 chromophobe (ChRCC) renal cell carcinomas, and the benign tumour renal oncocytoma (RO, n = 11). (3) Results:PRR is expressed in all the tumour subtypes, with higher mean staining intensity in ChRCCs and ROs. A high expression of PRR at the tumour centre and at the infiltrative front of CCRCC tissues is significantly associated with high grade, tumour diameter, local invasion and stage, and with high mortality risk by UCLA integrated staging system (UISS) scale. (4) Conclusions: These findings indicate that PRR is associated with the development and progression of renal tumours. Its potential as a novel biomarker for RCC diagnosis/prognosis and as a promising therapeutic target should be taken into account in the future.
Entities:
Keywords:
(Pro)renin receptor; prognosis; renal cell carcinoma; renin–angiotensin system
Authors: Chiara Recarti; Teresa Maria Seccia; Brasilina Caroccia; Abril Gonzales-Campos; Giulio Ceolotto; Livia Lenzini; Lucia Petrelli; Anna Sandra Belloni; William E Rainey; Juerg Nussberger; Gian Paolo Rossi Journal: J Hypertens Date: 2015-05 Impact factor: 4.844
Authors: Alexis A Gonzalez; Lucienne S Lara; Christina Luffman; Dale M Seth; Minolfa C Prieto Journal: Hypertension Date: 2011-02-14 Impact factor: 10.190
Authors: Minolfa C Prieto; Dustyn E Williams; Liu Liu; Kimberly L Kavanagh; John J Mullins; Kenneth D Mitchell Journal: Am J Physiol Renal Physiol Date: 2010-11-10